Uses of Sotalol HCl 80 mg: - Arrhythmia Supraventricular arrhythmias, Ventricular arrhythmias, Acute arrhythmias Bronchial asthma or history of COPD, sick sinus syndrome, symptomatic sinus bradycardia, cardiogenic shock. 2nd and 3rd degree AV block, untreated phaeochromocytoma, torsades de pointes, congenital or acquired long QT syndromes, uncontrolled cardiac failure, cardiogenic shock, metabolic acidosis, hypotension, severe peripheral arterial disease, Raynaud's disease, anaesthesia that causes myocardial depression. Renal impairment (CrCl <10 mL/min). Concomitant use w/ Ca channel blockers (e.g. verapamil and diltiazem).

Anti adrenergic agent (Beta blockers)

Sotalol is a non-cardioselective beta-blocker. It increases sinus cycle length, slows heart rate, decreases AV nodal conduction and increases AV nodal refractoriness. It also prolongs AV monophasic action potentials. However, it lacks intrinsic sympathomimetic and membrane-stabilising properties.

How to use Sotalol Hydrochloride: Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Sotalol Hydrochloride may be taken with or without food, but it is better to take it at a fixed time. Avoid Sotalol Hydrochloride with dairy products such as milk, cheese, curd, butter, paneer and ice cream. Administration: Should be taken on an empty stomach. Take 1-2 hr before meals. Adult Dose: Oral Supraventricular and ventricular arrhythmias Adult: Initially, 80 mg/day as single or in 2 divided doses, increased gradually every 2-3 days. Usual dose: 160-320 mg/day in 2 divided doses. Life-threatening ventricular arrhythmias Adult: Initially, 80 mg bid, increased gradually every 3 days to 240-320 mg/day in divided doses if needed. Maintenance: 160-320 mg/day in divided doses. Max: 480-640 mg in divided doses. Renal Dose: Renal impairment: CrCl (ml/min) Dosage Recommendation 30-60 Half the usual dose. 10-30 Quarter the usual dose. <10 Not recommended.

May increase risk of bradycardia w/ digoxin. May increase risk of arrhythmias w/ diuretics. May potentiate rebound HTN w/ clonidine. May prolong refractoriness w/ disopyramide, quinidine, procainamide, amiodarone and bepridil. May prolong QT interval w/ TCAs, phenothiazines, terfenadine and astemizole. Increased risk of torsades de pointes w/ K-depleting diuretics, erythromycin IV, halofantrine, pentamidine, and quinolones. May prolong neuromuscular blockade of tubocurarine. May reduce response to insulin and oral hypoglycaemics. Potentially Fatal: Additive effect on AV conduction and ventricular function w/ verapamil and diltiazem.

Bronchial asthma or history of COPD, sick sinus syndrome, symptomatic sinus bradycardia, cardiogenic shock. 2nd and 3rd degree AV block, untreated phaeochromocytoma, torsades de pointes, congenital or acquired long QT syndromes, uncontrolled cardiac failure, cardiogenic shock, metabolic acidosis, hypotension, severe peripheral arterial disease, Raynaud's disease, anaesthesia that causes myocardial depression. Renal impairment (CrCl <10 mL/min). Concomitant use w/ Ca channel blockers (e.g. verapamil and diltiazem).

Common - Dizziness - Fatigue - Slow heart rate - Breathlessness - Weakness >10% Dyspnea (21%),Dizziness (20%),Fatigue (20%),Bradycardia (16%),Chest pain (16%),Palpitation (14%),Weakness (13%),Lightheadedness (12%) 1-10% Nausea/vomiting (10%),Edema (8%),Headache (8%),Sleep disturbances (8%),Abnormal ECG (7%),Diarrhea (7%),Extremity pain (7%),Hypotension (6%),Mental confusion (6%),Congestive heart failure (5%),Itching/rash (5%),Syncope (5%),Anxiety (4%),Depression (4%),Torsades de pointes or new ventricular tachycardia/fibrillation in patients with supraventricular arrhythmia (4%),Peripheral vascular disorders (3%),Impotence (2%),Proarrhythmic effect (1.5-2%),Torsades de pointes with history of sustained ventricular tachycardia (1%) Frequency Not Defined Catechol hypersensitivity after abrupt withdrawal,Increased insulin requirement in diabetics Potentially Fatal: Polymorphic ventricular tachycardia (very rare). Rebound hypertension.

Its use throughout pregnancy should be avoided unless it is absolutely necessary as it crosses the placenta and may cause foetal bardycardia. Infants should not be fed with breast milk from mothers being treated with Sotalol

Precaution: Patients w/ well-compensated heart failure, myasthenia gravis, DM, 1st degree AV block. May mask symptoms of hyperthyroidism and hypoglycaemia. May worsen psoriasis. Patients undergoing major surgery requiring general anaesth. Avoid abrupt withdrawal as it may precipitate thyroid storm and exacerbate angina and MI. Renal impairment. Pregnancy and lactation. Monitoring Parameters Monitor BP, heart rate, serum creatinine; Mg and K levels.

Overdosage causes excessive bradycardia and hypotension; congestive heart failure, bronchospasm and hypoglycemia.

Store in a cool and dry place, protected from light.

Anti adrenergic agent (Beta blockers)

Sotalol is a non-cardioselective beta-blocker. It increases sinus cycle length, slows heart rate, decreases AV nodal conduction and increases AV nodal refractoriness. It also prolongs AV monophasic action potentials. However, it lacks intrinsic sympathomimetic and membrane-stabilising properties.

Its use throughout pregnancy should be avoided unless it is absolutely necessary as it crosses the placenta and may cause foetal bardycardia. Infants should not be fed with breast milk from mothers being treated with Sotalol